http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
-
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
-
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
-
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Applied DNA Sciences (APDN) Prices 5.64M Share Offering at $0.609/sh
-
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Applied DNA Sciences (APDN) Announces Joint Development Agreement to Integrate Linea IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
-
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
-
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
-
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
-
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
-
Applied DNA Sciences (APDN) Extends Application of Linea IVT Platform to saRNA
-
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
-
Applied DNA (APDN) Ships First saRNA IVT Template Generated by Linea DNA Platform
-
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
-
Applied DNA Sciences (APDN) Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform
-
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
-
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
-
Applied DNA Sciences (APDN) Advances Commercialization of Linea IVT Platform
-
Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
-
Applied DNA Sciences (APDN) Announces Availability and First Customer Shipment of New Linea IVT Evaluation Kit
-
Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit
-
Applied DNA Sciences (APDN) Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production
-
Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production
-
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update
-
Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023
-
Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences
-
Applied DNA Sciences (APDN) Acquires RNA Polymerase Developer Spindle Biotech
-
Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT(TM) Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach
-
Applied DNA Announces Presentation at Upcoming Healthcare Investor Conference
-
Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update
-
Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023
-
Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal
-
Applied DNA Sciences (APDN) Achieves Milestone for Large-Scale linearDNA Production, Delivers Largest Single Shipment by Volume to Date
-
Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date
-
Applied DNA Sciences (APDN) Submits Validation Package to New York State Department of Health for Approval of Pharmacogenomic Assay
-
Applied DNA Submits Validation Package to New York State Department of Health for Approval of Pharmacogenomic (PGx) Assay
-
Applied DNA Sciences (APDN) announces $1.5m New York State award for cGMP linearDNA
-
Applied DNA Announces New York State Award Valued at Up To $1.5 Million to Support Establishment of cGMP linearDNA™ Production Capacity on Long Island, New York
-
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
-
Applied DNA to Report First Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, February 9, 2023
-
Applied DNA Sciences (APDN) Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
-
Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
-
Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results
-
Applied DNA to Report Fiscal 2022 Fourth Quarter and Year End Financial Results on December 14, 2022
-
Applied DNA to Establish North America’s First Enzymatic (Cell Free) Large-Scale cGMP DNA Manufacturing Capacity in Suffolk County, New York
-
Applied DNA Sciences (APDN) Announces Receipt of Largest Single Purchase Order for LinearDNA To-Date
-
Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date
-
Applied DNA’s Biotherapeutics Subsidiary Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
-
Applied DNA Sciences (APDN), Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications

